POLE and neoplasm: To define the extent of the problem of ascribing pathogenicity to POLE mutations in clinical practice, we identified 296/3840 (7.7%) tumours with a somatic POLE mutation from EC cohorts other than TCGA 6, 7, 9, 10, 11, 12, 13, 14, 15, 17, 18, 19, 20, 21, 22, 24, 25 (Table 5 and supplementary material, Table S3).